Shire PLC Company Profile (NASDAQ:SHPG)


Shire PLC logoShire plc is a biotech company focused on serving people with rare diseases and other specialized conditions. The Company's segment is engaged in research, development, licensing, manufacturing, marketing, distribution and sale of specialist medicines. It focuses its development resources on projects in various therapeutic areas (TAs), including Neuroscience, Ophthalmology, Hematology, Oncology, Immunology, Gastrointestinal (GI)/Metabolic/Endocrinology Diseases. Its Hematology products include ADVATE (Antihemophilic Factor (Recombinant)), ADYNOVATE/ADYNOVI (Antihemophilic Factor (Recombinant), PEGylated)), RIXUBIS (Coagulation Factor IX (Recombinant)), VONVENDI (von Willebrand factor (Recombinant)) and FEIBA (Anti-Inhibitor Coagulant Complex). Its Genetic Diseases products include CINRYZE (C1 esterase inhibitor (human)), FIRAZYR (icatibant), ELAPRASE (idursulfase), REPLAGAL (agalsidase alfa) and VPRIV (velaglucerase alfa).

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Drug Manufacturers - Major
  • Sub-Industry: N/A
  • Symbol: NASDAQ:SHPG
  • CUSIP: N/A
  • Web:
  • Market Cap: $52.77 billion
  • Outstanding Shares: 297,854,000
Average Prices:
  • 50 Day Moving Avg: $178.41
  • 200 Day Moving Avg: $175.21
  • 52 Week Range: $161.09 - $209.22
  • Trailing P/E Ratio: 181.72
  • Foreward P/E Ratio: 10.35
  • P/E Growth: 0.89
Sales & Book Value:
  • Annual Revenue: $13.26 billion
  • Price / Sales: 3.98
  • Book Value: $98.66 per share
  • Price / Book: 1.80
  • Annual Dividend: $0.80
  • Dividend Yield: 0.5%
  • EBIDTA: $5.31 billion
  • Net Margins: 1.62%
  • Return on Equity: 14.81%
  • Return on Assets: 6.52%
  • Debt-to-Equity Ratio: 0.70%
  • Current Ratio: 1.25%
  • Quick Ratio: 0.57%
  • Average Volume: 987,008 shs.
  • Beta: 1.53
  • Short Ratio: 1.07

Frequently Asked Questions for Shire PLC (NASDAQ:SHPG)

What is Shire PLC's stock symbol?

Shire PLC trades on the NASDAQ under the ticker symbol "SHPG."

How often does Shire PLC pay dividends? What is the dividend yield for Shire PLC?

Shire PLC announced a dividend on Friday, February 24th. Stockholders of record on Friday, March 10th will be paid a dividend of $0.771 per share on Tuesday, April 25th. The ex-dividend date is Wednesday, March 8th. This is an increase from Shire PLC's previous dividend of $0.14. View Shire PLC's Dividend History.

How were Shire PLC's earnings last quarter?

Shire PLC (NASDAQ:SHPG) announced its quarterly earnings data on Tuesday, May, 2nd. The company reported $3.63 earnings per share for the quarter, beating the consensus estimate of $3.22 by $0.41. The business earned $3.57 billion during the quarter. Shire PLC had a return on equity of 14.81% and a net margin of 1.62%. The firm's revenue was up 109.0% on a year-over-year basis. During the same period in the prior year, the firm earned $2.12 EPS. View Shire PLC's Earnings History.

What guidance has Shire PLC issued on next quarter's earnings?

Shire PLC issued an update on its FY17 earnings guidance on Tuesday, May, 2nd. The company provided earnings per share guidance of $14.60-15.20 for the period, compared to the Thomson Reuters consensus earnings per share estimate of $15.00. The company issued revenue guidance of $14.5-14.8 billion, compared to the consensus revenue estimate of $15.23 billion.

Where is Shire PLC's stock going? Where will Shire PLC's stock price be in 2017?

18 analysts have issued 12-month target prices for Shire PLC's stock. Their forecasts range from $161.09 to $242.00. On average, they expect Shire PLC's stock price to reach $210.87 in the next twelve months. View Analyst Ratings for Shire PLC.

What are analysts saying about Shire PLC stock?

Here are some recent quotes from research analysts about Shire PLC stock:

  • 1. Jefferies Group LLC analysts commented, "SHPG posted strong 4Q16 revs ($3.8B vs $3.7B JEF) and EPS ($3.37 vs $3.26 JEF) as nearly all core franchises performed well. In particular, GI and Orphan Diseases showed strength. As for legacy BXLT, Immunoglobulins and Hemophilia performed well while Inhibitors lagged. We like the setup for 2017. If mgt executes on core brands, the Xiidra launch, and the BXLT integration, we could envision share price outperformance, augmented by significant deleveraging." (2/17/2017)
  • 2. According to Zacks Investment Research, "Shire is a leader in the ADHD market with drugs like Vyvanse and Intuniv. The adult ADHD space is one of the largest and fastest growing segments and a potential approval of SHP465 will further strengthen Shire’s franchise. It has expanded its presence in the gastrointestinal, neuroscience and rare disease markets through strategic acquisitions. The NPS Pharma acquisition has strengthened the company's GI franchise. Moreover, Shire’s agreement to license global rights to Pfizer’s PF-00547659 will strengthen the company’s GI pipeline further. The company updated its annual guidance with expectations of $700 million of operating cost synergies from the Baxalta acquisition (completed in Jun 2016), up from the earlier projection of $500 million. Estimates have been moving up ahead of the company’s Q3 earnings results. However, headwinds remain in the form of generic competition and unfavorable currency movements." (10/21/2016)

Are investors shorting Shire PLC?

Shire PLC saw a drop in short interest during the month of May. As of May 15th, there was short interest totalling 771,360 shares, a drop of 23.3% from the April 28th total of 1,005,646 shares. Based on an average daily trading volume, of 847,958 shares, the short-interest ratio is presently 0.9 days.

Who are some of Shire PLC's key competitors?

Who owns Shire PLC stock?

Shire PLC's stock is owned by many different of retail and institutional investors. Top institutional shareholders include Jennison Associates LLC (2.17%), Waddell & Reed Financial Inc. (1.15%), FMR LLC (0.21%), Vanguard Group Inc. (0.17%), BlackRock Inc. (0.16%) and Janus Capital Management LLC (0.46%). View Institutional Ownership Trends for Shire PLC.

Who sold Shire PLC stock? Who is selling Shire PLC stock?

Shire PLC's stock was sold by a variety of institutional investors in the last quarter, including Jennison Associates LLC, Waddell & Reed Financial Inc., TIAA CREF Investment Management LLC, Marshall Wace LLP, Goldman Sachs Group Inc., FMR LLC, Point72 Asset Management L.P. and UBS Asset Management Americas Inc.. View Insider Buying and Selling for Shire PLC.

Who bought Shire PLC stock? Who is buying Shire PLC stock?

Shire PLC's stock was acquired by a variety of institutional investors in the last quarter, including BlackRock Inc., Glenview Capital Management LLC, Boston Partners, Jana Partners LLC, New South Capital Management Inc., Renaissance Technologies LLC, Capital Fund Management S.A. and Bank of America Corp DE. View Insider Buying and Selling for Shire PLC.

How do I buy Shire PLC stock?

Shares of Shire PLC can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

How much does a share of Shire PLC stock cost?

One share of Shire PLC stock can currently be purchased for approximately $177.18.

Analyst Ratings

Consensus Ratings for Shire PLC (NASDAQ:SHPG) (?)
Ratings Breakdown: 1 Sell Rating, 3 Hold Ratings, 14 Buy Ratings
Consensus Rating:Buy (Score: 2.72)
Consensus Price Target: $210.87 (19.01% upside)

Analysts' Ratings History for Shire PLC (NASDAQ:SHPG)
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
5/25/2017Sanford C. BernsteinDowngradeOutperform -> Market Perform$209.22 -> $161.09LowView Rating Details
5/18/2017Royal Bank of CanadaSet Price TargetBuy$221.00LowView Rating Details
5/19/2017HSBC Holdings plcDowngradeHold -> ReduceLowView Rating Details
4/20/2017Jefferies Group LLCSet Price TargetBuy$239.00LowView Rating Details
4/17/2017Goldman Sachs Group IncBoost Price TargetOverweight$202.00 -> $214.00LowView Rating Details
3/9/2017Liberum CapitalInitiated CoverageBuy -> BuyLowView Rating Details
3/7/2017Barclays PLCInitiated CoverageOverweightN/AView Rating Details
2/17/2017GuggenheimReiterated RatingNeutralN/AView Rating Details
12/23/2016BTIG ResearchReiterated RatingBuy$242.00N/AView Rating Details
12/2/2016Societe GeneraleInitiated CoverageBuyN/AView Rating Details
11/14/2016Leerink SwannSet Price TargetBuy$198.00N/AView Rating Details
11/7/2016JPMorgan Chase & Co.Reiterated RatingOverweightN/AView Rating Details
11/3/2016Citigroup IncReiterated RatingBuyN/AView Rating Details
11/2/2016Deutsche Bank AGReiterated RatingBuyN/AView Rating Details
10/23/2016BNP ParibasReiterated RatingBuyN/AView Rating Details
10/8/2016Shore CapitalReiterated RatingBuyN/AView Rating Details
10/1/2016Piper Jaffray CompaniesSet Price TargetHold$201.00N/AView Rating Details
6/3/2016Morgan StanleyReiterated RatingOverweightN/AView Rating Details
5/26/2016Stifel NicolausInitiated CoverageBuy$230.00N/AView Rating Details
5/23/2016Bryan, Garnier & CoInitiated CoverageBuyN/AView Rating Details
5/3/2016Cowen and CompanyReiterated RatingBuyN/AView Rating Details
3/30/2016Bank of America CorpReiterated RatingBuyN/AView Rating Details
2/26/2016Cantor FitzgeraldInitiated CoverageBuyN/AView Rating Details
2/13/2016Northland SecuritiesReiterated RatingBuyN/AView Rating Details
2/8/2016Susquehanna Bancshares IncLower Price TargetPositive$280.00 -> $220.00N/AView Rating Details
1/18/2016Credit Suisse Group AGUpgradeBuyN/AView Rating Details
10/21/2015William BlairReiterated RatingOutperform$276.00N/AView Rating Details
7/16/2015Berenberg BankInitiated CoverageBuyN/AView Rating Details
(Data available from 5/27/2015 forward)


Earnings History for Shire PLC (NASDAQ:SHPG)
Earnings by Quarter for Shire PLC (NASDAQ:SHPG)
Earnings History by Quarter for Shire PLC (NASDAQ:SHPG)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
5/2/2017Q1 17$3.22$3.63$3.57 billionViewListenView Earnings Details
2/16/2017Q416$3.24$3.37$3.78 billion$3.81 billionViewN/AView Earnings Details
11/1/2016Q316$3.21$3.17$3.57 billion$3.45 billionViewN/AView Earnings Details
8/2/2016Q216$3.03$3.38$2.28 billion$2.43 millionViewN/AView Earnings Details
4/29/2016Q1$3.05$3.19$1.71 billion$1.71 billionViewListenView Earnings Details
2/11/2016Q415$2.89$2.97$1.69 million$1.72 billionViewListenView Earnings Details
10/23/2015Q315$2.87$3.24$1.63 billion$1.58 billionViewListenView Earnings Details
7/23/2015Q215$2.81$2.63$1.59 billion$1.56 billionViewListenView Earnings Details
4/30/2015Q115$2.56$2.84$1.47 billion$1.49 billionViewN/AView Earnings Details
2/12/2015Q115$2.68$2.63$1.53 billion$1.58 billionViewN/AView Earnings Details
10/24/2014Q314$2.47$2.93$1.46 billion$1.55 billionViewListenView Earnings Details
7/18/2014Q214$2.45$2.67$1.45 billion$1.50 billionViewN/AView Earnings Details
5/1/2014Q114$2.22$2.36$1.38 billion$1.35 billionViewN/AView Earnings Details
2/13/2014Q413$2.02$2.26$1.28 billion$1.33 billionViewN/AView Earnings Details
10/24/2013Q213$1.65$1.77$1.23 billion$1.24 billionViewN/AView Earnings Details
7/25/2013$1.60$1.79$1.21 billion$1.28 billionViewN/AView Earnings Details
5/2/2013Q113$1.56$1.63$1.21 billion$1.16 billionViewN/AView Earnings Details
2/14/2013Q412$1.58$1.58$1.20 billion$1.20 billionViewN/AView Earnings Details
10/25/2012$1.47$1.36ViewN/AView Earnings Details
8/1/2012$1.52$1.68ViewN/AView Earnings Details
4/26/2012$0.52$1.24ViewN/AView Earnings Details
2/9/2012$0.48$0.44ViewN/AView Earnings Details
10/28/2011$1.31$1.28ViewN/AView Earnings Details
7/28/2011$1.24$1.33ViewN/AView Earnings Details
4/28/2011$1.18$1.23ViewN/AView Earnings Details
2/10/2011$1.04$1.03ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)


Earnings Estimates for Shire PLC (NASDAQ:SHPG)
2017 EPS Consensus Estimate: $14.89
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20174$3.22$3.36$3.31
Q2 20174$3.60$3.69$3.64
Q3 20174$3.66$3.89$3.82
Q4 20174$3.93$4.26$4.13
(Data provided by Zacks Investment Research)


Current Dividend Information for Shire PLC (NASDAQ:SHPG)
Most Recent Dividend:4/25/2017
Annual Dividend:$0.80
Dividend Yield:0.45%
Payout Ratio:51.95% (Trailing 12 Months of Earnings)
5.33% (Based on This Year's Estimates)
4.67% (Based on Next Year's Estimates)
Dividend Payments by Quarter for Shire PLC (NASDAQ:SHPG)

Dividend History by Quarter for Shire PLC (NASDAQ:SHPG)
AnnouncedPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
(Data available from 1/1/2013 forward)

Insider Trades

Insider Trading History for Shire PLC (NASDAQ:SHPG)
No insider trades for this company have been tracked by


Headline Trends for Shire PLC (NASDAQ:SHPG)
Latest Headlines for Shire PLC (NASDAQ:SHPG)
DateHeadline logoShire PLC (SHPG) Cut to "Market Perform" at Sanford C. Bernstein - May 27 at 1:24 PM logoSHPG Crosses Below Key Moving Average Level - Nasdaq - May 27 at 4:45 AM logoShire to Participate at the Jefferies Healthcare Conference - May 26 at 6:59 AM logoShire (SHPG): Positive Topline Phase 3 Results for Lanadelumab (SHP643) in Patients With Hereditary Angioedema (HAE) - Slideshow - May 23 at 7:12 PM logoShire and tiny Lexington biotech say hemophilia drug trial misses mark - May 22 at 6:51 PM logoMerrill Lynch Raises Price Targets on 5 Stocks With Blow-Out Earnings - May 22 at 9:01 AM logoShire PLC (SHPG) to Post FY2018 Earnings of $18.44 Per Share, SunTrust Banks Forecasts - May 22 at 8:06 AM logoShire PLC (SHPG) Downgraded by HSBC Holdings plc - May 20 at 10:40 AM logoShire plc (SHPG) to Offer New Research Into Chronic Hypoparathyroidism at the European Congress of Endocrinology ... - - May 20 at 8:11 AM logoShire plc (SHPG) to Offer New Research Into Chronic Hypoparathyroidism at the European Congress of Endocrinology, May 20-23 - May 20 at 12:31 AM logoShire PLC (SHPG) Given a $221.00 Price Target at Royal Bank of Canada - May 19 at 7:16 PM logoShire's lanadelumab successful in late-stage HAE study; shares ahead 6% premarket - May 19 at 9:55 AM logoShire (SHPG) Says Lancet Publishes Phase 2 Results from Anti-MAdCAM Antibody Showing Increased Remission Rates in Patients with Moderate-to-Severe UC - May 19 at 9:55 AM logoShire To Highlight New Research On Chronic Hypoparathyroidism - May 19 at 9:55 AM logoActive Wall Street: Blog Coverage: Shire's Stock Price Jumped on Positive Results in Hereditary Angioedema Treatment - May 19 at 9:55 AM logoDrugmaker Leads Industry Gains Thursday On Rare Disease Trial - May 19 at 9:55 AM logoShire to Highlight New Research Into Chronic Hypoparathyroidism at the European Congress of Endocrinology - May 19 at 9:55 AM logoBlog Coverage: Shire's Stock Price Jumped on Positive Results in Hereditary Angioedema Treatment - May 19 at 9:55 AM logoShire (SHPG) Says Lancet Publishes Phase 2 Results from Anti-MAdCAM Antibody Showing Increased Remission ... - - May 18 at 1:08 PM logoSunTrust Banks Analysts Lower Earnings Estimates for Shire PLC (SHPG) - May 18 at 9:00 AM logoShire PLC (SHPG) to Post Q2 2017 Earnings of $3.62 Per Share, SunTrust Banks Forecasts - May 17 at 7:42 AM logo[$$] Health-Care Investor Agent Capital Seeks $100 Million Fund - May 16 at 7:45 PM logoETFs with exposure to Shire Plc : May 15, 2017 - May 15 at 7:01 PM logoShire PLC (SHPG) Given Average Rating of "Buy" by Brokerages - May 8 at 10:08 AM logoStock Traders Buy Large Volume of Shire PLC Call Options (SHPG) - May 6 at 7:20 AM logoETFs with exposure to Shire Plc : May 5, 2017 - May 5 at 8:09 PM logoQ2 2017 EPS Estimates for Shire PLC (SHPG) Reduced by Analyst - May 5 at 8:02 AM logoShire PLC (SHPG) Issues Quarterly Earnings Results - May 4 at 8:10 PM logoShire: Post-Earnings Analysis - May 4 at 8:09 PM logoShire Plc :SHPG-US: Earnings Analysis: Q1, 2017 By the Numbers : May 4, 2017 - May 4 at 8:09 PM logoShire PLC (SHPG) Posts Quarterly Earnings Results, Beats Expectations By $0.41 EPS - May 4 at 6:32 PM logoShire PLC (SHPG) Posts Earnings Results, Beats Expectations By $0.41 EPS - May 4 at 2:24 PM logoEarnings Reaction History: Shire plc, 22.2% Follow-Through Indicator, 2.4% Sensitive - Nasdaq - May 3 at 5:59 PM logoShire (SHPG), Parion Sciences Enter Pact to Advance P-321 for Ophthalmic Indications - - May 3 at 5:59 PM logoShire (SHPG) Beats on Q1 Earnings & Sales, Reiterates View - Yahoo Finance - May 3 at 5:59 PM logoShire plc (SHPG) Tops Q1 EPS by 34c, Sales In-Line - - May 3 at 5:59 PM logoShire plc Announces 75% Increase In Q1 Profit - May 3 at 12:01 PM logoShire plc (SHPG) Tops Q1 EPS by 34c, Sales In-Line - May 3 at 12:01 PM logoShire Plc (SHPG) Q1 2017 Results - Earnings Call Transcript - May 3 at 12:01 PM logoShire Delivers Strong Q1 2017 Revenue Growth While Advancing Late-stage Pipeline - May 3 at 12:01 PM logoShire (SHPG) Beats on Q1 Earnings & Sales, Reiterates View - May 3 at 12:01 PM logoMomenta (MNTA) Q1 Loss Narrower than Expected, Sales Beat - May 3 at 12:01 PM logoQ1 2017 EPS Estimates for Shire PLC Decreased by SunTrust Banks (SHPG) - May 3 at 7:30 AM logoShire PLC (SHPG) Receiving Somewhat Positive Media Coverage, Analysis Finds - May 3 at 1:01 AM logoShire PLC (SHPG) Releases Earnings Results, Beats Estimates By $0.36 EPS - May 2 at 11:20 AM logoShire PLC (SHPG) Releases FY17 Earnings Guidance - May 2 at 10:46 AM logoShire tops Street 1Q forecasts - May 2 at 7:42 AM logoEarnings Scheduled For May 2, 2017 - May 2 at 5:05 AM logoWilliam Blair Weighs in on Shire PLC's Q1 2017 Earnings (SHPG) - May 1 at 7:07 AM logoShire PLC (SHPG) Receiving Somewhat Favorable Media Coverage, Analysis Finds - April 29 at 3:15 PM



Shire PLC (SHPG) Chart for Saturday, May, 27, 2017

This page was last updated on 5/27/2017 by Staff